Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.
Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, Watkinson P, Khunti K, Harnden A, Coupland CAC, Channon KM, Mills NL, Sheikh A, Hippisley-Cox J. · 2022
Read Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. by Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, Watkinson P, Khunti K, Harnden A, Coupland CAC, Channon KM, Mills NL, Sheikh A, Hippisley-Cox J. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8863574.txt.
Introduction
Patone and co-authors weigh heart inflammation risks after COVID-19 vaccination and after infection. Reports of myocarditis followed the vaccine rollout. Trials were too small to catch such rare events. The team used a self-controlled case series in England. It covered people aged 16 or older. Three vaccines and positive virus tests were compared.
Myocarditis risk rose after some vaccine doses. The extra cases were small: between one and six per million after a first dose. A second mRNA-1273 dose added about ten per million. Infection carried a far larger risk. A positive test added about 40 extra cases per million. Pericarditis and arrhythmia risks also rose after infection, not vaccination. The vaccine-linked rise appeared only under age 40. The study frames a clear risk comparison.
Catalog record
| CREATOR | Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, Watkinson P, Khunti K, Harnden A, Coupland CAC, Channon KM, Mills NL, Sheikh A, Hippisley-Cox J. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 68 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection By Martina Patone, Xue W. Mei, Lahiru Handunnetthi, Sharon Dixon, Francesco Zaccardi, Manu Shankar-Hari, Peter Watkinson, Kamlesh Khunti, Anthony Harnden, Carol A. C. Coupland, Keith M. Channon, Nicholas L. Mills Published in: Nature Medicine DOI: 10.1038/s41591-021-01630-0 ABSTRACT Although myocarditis and pericarditis were not observed as adverse events in coronavirus disease 2019 (COVID-19) vaccine trials, there have been numerous reports of suspected cases following vaccination in the general population. We undertook a self-controlled case series study of people aged 16 or older vaccinated for COVID-19 in England between 1 December 2020 and 24 August 2021 to investigate hospital admission or death from myocarditis, pericarditis and cardiac arrhythmias in the 1–28 days following adenovirus (ChAdOx1, n = 20,615,911) or messenger RNA-based (BNT162b2, n = 16,993,389; mRNA-1273, n = 1,006,191) vaccines or a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive test (n = 3,028,867). We found increased risks of myocarditis associated with the first dose of ChAdOx1 and BNT162b2 vaccines and the first and second doses of the mRNA-1273 vaccine over the 1–28 days postvaccination period, and after a SARS-CoV-2 positive test. We estimated an extra two (95% confidence interval (CI) 0, 3), one (95% CI 0, 2) and six (95% CI 2, 8) myocarditis events per 1 million people vaccinated with ChAdOx1, BNT162b2 and mRNA-1273, respectively, in the 28 days following a first dose and an extra ten (95% CI 7, 11) myocarditis events per 1 million vaccinated in the 28 days after a second dose of mRNA-1273. This compares with an extra 40 (95% CI 38, 41) myocarditis events per 1 million patients in the 28 days following a SARS-CoV-2 positive test. We also observed increased risks of pericarditis and cardiac arrhythmias following a positive SARS-CoV-2 test. Similar associations were not observed with any of the COVID-19 vaccines, apart from an increased risk of arrhythmia following a second dose of mRNA-1273. Subgroup analyses by age showed the increased risk of myocarditis associated with the two mRNA vaccines was present only in those younger than 40. MAIN By the end of September 2021, more than 6.3 billion doses of COVID-19 vaccination had been administered worldwide1. Clinical trials of COVID-19 vaccines were underpowered to detect the rare adverse events that are important for risk–benefit evaluations and to inform clinical practice postvaccination. Therefore, identifying such rare adverse events is now a global scientific priority. As of 4 November 2021, there have been 1,783 reports to the United States Vaccine Adverse Event Reporting System (VAERS) of cases of heart inflammation, namely myocarditis or pericarditis, among people aged 12–29 years who received COVID-19 vaccines, in particular following mRNA vaccination, that is, BNT162b2 and mRNA-1273 vaccines2. As of 9 July 2021, the European Medicines Agency (EMA) has reported 145 cases of myocarditis and 138 cases of pericarditis out of 177 million doses of the BNT162b2 vaccine, and 9 cases of myocarditis and 19 cases of pericarditis out of 20 million doses of the mRNA-1273 vaccine3. In Israel, 275 cases of myocarditis were reported between December 2020 and May 2021 among more than 5 million people vaccinated with the BNT162b2 vaccine4. No association between ChAdOx1 vaccine and myocarditis or pericarditis has been reported. The same reports showed that these events are more likely to occur in adolescent and young adults, mostly after the second dose. Evaluation of the risks of adverse events following vaccination or SARS-CoV-2 infection in different age groups provides crucial information to determine whether the risks from the vaccine outweighs the risks following a positive SARS-CoV-2 test. In England, the vaccination campaign began on 8 December 2020 with the BNT162b2 vaccine followed by the ChAdOx1 vaccine on 4 January 2021. In the first phase, priority was given to the most vulnerable, in a schedule based primarily on age. The mRNA-1273 vaccine became available in England on 13 April 2021. Since 7 April 2021, ChAdOx1 vaccine has not been recommended for individuals younger than 30 years of age, and since 7 May 2021 for individuals younger than 40 years of age. The English National Immunisation (NIMS) Database of COVID-19 vaccination includes data on vaccine type, date and doses for all people vaccinated in England. We linked NIMS, at individual patient level, to national data for mortality, hospital admissions and SARS-CoV-2 infection data to examine the associations between the first and second dose of ChAdOx1, BNT162b2 or mRNA-1273 vaccines and cardiac adverse events: myocarditis, pericarditis or cardiac arrhythmias. We used the same population to investigate the associations between a positive SARS-CoV-2 test (before or after vaccination) as a secondary exposure and the same cardiac adverse events. We also assessed risks for the same outcomes following vaccination or a SARS-CoV-2 positive test in younger persons (<40 years old). Incidence rate ratios, the rate of hospital admission or death from each outcome in risk periods after vaccination or a positive test relative to baseline periods, were estimated using self-controlled case series (SCCS) methodology5,6. RESULTS A total of 38,615,491 adults had been vaccinated with at least one dose of ChAdOx1 (n = 20,615,911), BNT162b2 (n = 16,993,389) or mRNA-1273 (n = 1,006,191) in England between 1 December 2020 and 24 August 2021 (Table 1). Of these, 32,095,748 had received two doses of either ChAdOx1 (n = 19,754,224, 95.8%), BNT162b2 (n = 11,972,733, 70.5%) or mRNA-1273 (n = 368,791, 36.7%). Individuals receiving the ChAdOx1 and BNT162b2 vaccine were older, on average, than those receiving the mRNA-1273 vaccine, as expected given that the mRNA-1273 vaccine roll-out began in April 2021 in the United Kingdom, when higher priority risk groups (including older people) had already received their vaccine.Table 1Baseline demographic characteristics of people receiving either ChAdOx1, BNT162b2 or mRNA-1273 vaccines or testing positive for SARS-CoV-2 virus (before or after vaccination), in England between 1 December 2020 and 24 August 2021. Data are presented as column % (counts)ChAdOx1BNT162b2mRNA-1273ChAdOx1BNT162b2mRNA-1273Positive SARS-CoV-2 test (amongst total vaccinated)One dose (at least) (n = 38,615,491)Two doses (n = 32,095,748)Total number of people20,615,91116,993,3891,006,19119,754,22411,972,733368,7913,028,867SexWomen43.3 (8,918,403)42.6 (7,233,091)29.9 (300,567)43.3 (8,559,325)47.2 (5,650,542)33.9 (125,120)45.7 (1,385,137)Men34.9 (7,191,428)31.8 (5,401,842)28.5 (286,893)34.9 (6,900,964)32.6 (3,906,666)26.4 (97,524)32.2 (974,389)Not recorded21.9 (4,506,080)25.6 (4,358,456)41.6 (418,731)21.7 (4,293,935)20.2 (2,415,525)39.6 (146,147)22.1 (669,341)AgeMean age (s.d.)55.2 (14.8)47.8 (21.7)32.3 (9.4)55.4 (14.7)55.5 (20.4)39.6 (7.3)44.5 (17.8)16–29 years5.2 (1,064,443)25.2 (4,285,600)41.4 (416,982)5.0 (988,291)10.4 (1,244,710)6.9 (25,382)24.4 (738,170)30–39 years7.8 (1,598,406)23.2 (3,945,405)36.4 (366,327)7.6 (1,494,285)20.7 (2,475,091)43.8 (161,412)19.0 (574,710)40+ years87.1 (17,953,062)51.6 (8,762,384)21.2 (222,882)87.4 (17,271,648)68.9 (8,252,932)49.3 (181,997)56.6 (1,715,987)EthnicityWhite55.5 (11,449,387)52.3 (8,887,419)40.1 (403,362)55.8 (11,019,453)57.8 (6,921,753)43.0 (158,719)52.6 (1,593,727)Indian1.5 (319,328)1.7 (288,641)0.7 (7,406)1.5 (304,100)1.8 (217,910)0.8 (2,975)2.4 (72,852)Pakistani1.0 (214,193)1.1 (183,917)0.7 (6,724)1.0 (191,755)0.9 (105,414)0.4 (1,474)2.1 (64,153)Bangladeshi0.4 (81,004)0.4 (62,128)0.3 (3,287)0.4 (74,743)0.3 (34,927)0.2 (684)0.7 (21,585)Other Asian0.7 (137,542)0.8 (134,649)0.7 (6,648)0.7 (129,169)0.8 (90,508)0.7 (2,488)1.1 (31,933)Black Caribbean0.5 (99,666)0.4 (62,101)0.3 (2,734)0.5 (91,098)0.4 (47,767)0.2 (664)0.5 (14,152)Black African0.7 (149,358)0.7 (115,282)0.6 (5,929)0.7 (134,635)0.6 (73,472)0.5 (1,679)0.9 (27,757)Chinese0.3 (53,279)0.3 (43,014)0.3 (3,261)0.3 (51,338)0.3 (30,662)0.5 (1,691)0.2 (4,585)Other ethnic group1.8 (366,361)1.9 (321,150)1.9 (19,313)1.7 (342,040)1.7 (208,462)1.8 (6,795)2.3 (69,725)Ethnicity not recorded37.6 (7,745,793)40.6 (6,895,088)54.4 (547,527)37.5 (7,415,893)35.4 (4,241,858)52.0 (191,622)37.3 (1,128,398)Number of dosesOne dose only4.1 (835,832)29.5 (5,007,083)63.3 (637,335)–––25.1 (759,352)Cardiac inflammation in the previous 2 yearsaPrevious myocarditis<0.1 (1,840)<0.1 (1,485)<0.1 (56)<0.1 (1,747)<0.1 (1,220)<0.1 (15)<0.1 (451)Previous pericarditis<0.1 (1,849)<0.1 (1,508)<0.1 (31)<0.1 (1,771)<0.1 (1,285)<0.1 (8)<0.1 (346)Previous cardiac arrhythmia2.6 (538,564)2.9 (500,295)0.3 (2,969)2.6 (505,794)3.9 (466,724)0.3 (1,005)3.1 (92,985)aTwo years before 1 December 2020 Amongst those with at least one dose, there were 3,028,867 (7.8%) individuals who had a SARS-CoV-2 positive test. Of these, 2,315,669 (6.0%) individuals tested positive before vaccination;